Subscribe to our Newsletters !!
Dulbecco’s Modified Eagle Medium is perhaps the
Fetal Bovine Serum (FBS) holds great value in cell
The human metapneumovirus, more simply referred to
We are truly honored to share that HiMedia Laborat
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Welcome to the latest issue of Microbioz India. As
Researchers from Britain’s University of Oxford have developed a quick COVID-19 test able to spot the coronavirus in less than five minutes, researchers said on Thursday, adding it could be utilised in mass testing in airports and businesses.
The university said it expected to begin product development of the testing apparatus in early 2021 and have an approved device available six months afterwards.
The device can detect the coronavirus and distinguish it from other viruses with high precision, the researchers said in a pre-print study.
“Our method quickly finds intact virus particles,” said Professor Achilles Kapanidis, at Oxford’s Department of Physics, adding that this meant the test would be”easy, extremely rapid, and cost-effective”.
Rapid antigen tests are seen as crucial in rolling out mass-testing and re-opening economies while the coronavirus is still circulating, and the ones which are already in use are quicker and cheaper but less accurate than existing molecular PCR tests.
Siemens Healthineers on Wednesday announced the launch of a rapid antigen test kit in Europe to detect coronavirus infections, but cautioned that the sector may struggle to meet a surge in demand.
Even though the Oxford platform will only be ready next year, the evaluations may help manage the pandemic in time for next winter. Health officials have warned that the world will have to live with coronavirus even if a vaccine is developed.
“A significant concern for the upcoming winter months is the unpredictable effects of co-circulation of SARS-CoV-2 with other seasonal respiratory ailments,” said Dr Nicole Robb, of Warwick Medical School.
“We have demonstrated that our assay (test) can reliably distinguish between different viruses in clinical trials, a development that delivers an essential advantage in the next phase of the pandemic.”
